Skip to content
  • 6,799 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started

Sources sought

Audit & Recall Indefinite Delivery Indefinite Quantity (IDIQ) Contract

75F40124R00041

Food and Drug Administration, FDA Office of Acq Grant SVCS. All Other Support Services.

Response deadline

March 7, 2024 at 2:00 PM EST

Closed 969 days ago. Posted February 22, 2024. Scheduled to archive March 22, 2024.

Get the next one like this from Food and Drug Administration by email, the day it is posted.Find my opportunities

This one closed in 2024

11 like it are open now in all other support services

All 11 open in all other support services

Description

As published on SAM.gov.

The Food and Drug Administration (FDA) protects public health by coordinating, initiating, and/or monitoring regulatory and recall actions, reviewing and managing compliance policies and processes, and evaluating data to assess and enhance agency compliance activities. The Office of Regulatory Affairs (ORA) within FDA has substantially evolved its product safety and quality model to keep ahead of the possible risks in an ever-changing world of manufacturers and producers.

While import growth, rates have accelerated, so too has the need for highly standardized operations within the government and the marketplace. The new global implications have forced FDA to recognize major implications such as pressures to reduce cost, increase productivity and capitalize on quality improvement activities while maintaining strong global safety standards.

The Code of Federal Regulations (CFR) Title 21 Part 7 (21CFR7) governs the practices and procedures applicable to regulatory enforcement actions initiated by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and other laws that it administers. A recall is a firm's removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers.

A correction is further defined as the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product without its physical removal to some other location. Any firm may initiate a recall when its product is deemed to be in violation of FDA regulations and laws.

Throughout the execution of a recall, it is the FDA’s responsibility to provide guidance to recalling firms, determine the hazard posed by the recalled product, inform the public of potential health risks, and monitor firms’ recall effectiveness, in part, by conducting recall audit checks (RACs) at recalling firm’s consignees to determine whether the consignee received the recall notification and followed instructions in the notification.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. February 22, 2024

    Sources sought

    Due March 7, 2024 at 2:00 PM EST. SAM.gov, notice 3b3c103149c240c3a42867af923287dd

Points of contact